Navigation Links
Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
Date:12/11/2007

become infected with HBV this year.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation of the Phase 3 registration studies and/or our development of clevudine, the risk that adverse events could cause the cessation of the Phase 1 combination study and/or our development of R7128, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary ... announced on May 22 the actions that Ranbaxy ... conduct under prior management ( ... to support Ranbaxy in its efforts to address ... led to the investigations by the U.S. Department ...
(Date:5/22/2013)... 22. Mai 2013  Grifols, ein globales ... Barcelona , Spanien, präsentierte die ... höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den ... (AAT) auf ein Niveau anhebt, das innerhalb ... liegt. ATT-Mangel ist eine lebensbedrohliche, genetische Erkrankung, ...
(Date:5/22/2013)... Israel , May 22, 2013  Rosetta ... developer and provider of microRNA-based molecular diagnostics, announces that ... Chief Executive Officer of Rosetta Genomics, will deliver a ... place from June 3-6, 2013 in New York City.  ... 4 th at 2:00 p.m. Eastern time. ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical applications, has entered into a new, ... SANTE (SES) of Algiers, Algeria for the distribution ...
... BME (BioMedical Enterprises, Inc.), a developer and manufacturer ... United States launch of Speed™. It is the first ... to orthopaedic and podiatric surgeons. BME, the ... its extensive knowledge in memory metal implant design to ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Algeria 2Misonix Announces New Distribution Agreement for Algeria 3
(Date:5/22/2013)... Mass, May 23, 2013 Existing research shows that bicyclists ... of brain injury, but researchers at Boston Children,s Hospital ... showed a 20 percent decrease in deaths and injuries ... bicycle-motor vehicle collisions. , The cross-sectional study, conducted ... MD, MPH, Rebekah C. Mannix, MD, MPH of Boston ...
(Date:5/22/2013)... On May 16, 2012, LifeHealthPro reported ... funeral concierge can help families negotiate lower costs for all ... Financials announces their top 3 reasons to hire a ... the U.S. having dropped 7.3 percent from $55,438 to $51,404 ... costs 12.6% of an average U.S. households annual income. , ...
(Date:5/22/2013)... Dr. Andrew Satlin offers patients with ... the Laser Assisted New Attachment Procedure (LANAP). May is Stroke ... connections between gum disease and stroke. Periodontal disease is one ... today, and is linked to an increased risk for strokes ... infected gum pockets. , Periodontal disease is essentially an ...
(Date:5/22/2013)... NY (PRWEB) May 22, 2013 A new ... Health has found that of young people who visited fast ... and youth who were obese were more likely to use ... choices. It also found that young people eating at fast ... half as likely to use calorie information as those eating ...
(Date:5/22/2013)... Jury deliberations are now underway in Washington ... da Vinci lawsuit, Bernstein Liebhard LLP reports. According ... who allegedly died of da Vinci surgery complications following prostate ... from Intuitive Surgical, Inc. Among other things, they allege ... da Vinci Surgical System in its efforts to drive sales ...
Breaking Medicine News(10 mins):Health News:Rate of bicycle-related fatalities significantly lower in states with helmet laws 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 3Health News:For Stroke Awareness Month, Dr. Andrew Satlin is Raising Awareness of the Connections Between Gum Disease and Stroke and Offers Encino, CA Laser Gum Surgery for Treatment 2Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 2Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 2Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 4
... ... documentary film project entitled Now Serving. Now Serving will highlight the lives of four elderly Americans ... ... the launch of their blog site, My Apple Box , which catalogues the making of ...
... ... announced that MedFusion®, of Dallas, Texas, has signed a business agreement to license ... , ... March 17, 2010 -- Sunquest Information Systems, Inc. ® , a leading ...
... Imago Relationships launch an online ... - called an Avatar - who can help you make sense of your relationship problems. ... partner. , ... 17, 2010 -- Imago,s new "marriage counseling" Avatar doesn,t have a blue face and ...
... ... participating in a Strategic Leadership Development program for its current and potential physician leaders, ... ... Group is participating in a Strategic Leadership Development program for its current and ...
... Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that Robert Myers , the company,s President, will present at the Barclays Capital 2010 Global Healthcare Conference on ... ... , ... ...
... KNOXVILLE, Tenn. , March 16 TeamHealth Holdings, ... largest suppliers of outsourced healthcare professional staffing and administrative services ... States , today announced that its management will be presenting ... March 24, 2010 , at the Loews Miami Hotel, ...
Cached Medicine News:Health News:Announcing the Launch of My Apple Box 2Health News:Sunquest Information Systems Enters into Business Relationship with MedFusion of Dallas 2Health News:Avatar Meets Marriage Counseling; Take Imago Therapy for a Test Drive 2Health News:Avatar Meets Marriage Counseling; Take Imago Therapy for a Test Drive 3Health News:Summit Medical Group Prepares Physicians for Future Leadership 2Health News:Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 3
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
... is designed for rigid skeletal ... greater freedom in positioning the ... skeletal fixation is designed for ... sitting positions. Craniotomies can be ...
Endoscopes...
... borescopes are rigid endoscopes for general applications and ... The diameters of borescopes, i.e. rigid endoscopes, range ... directions from 0 up to a 120 retrospection, ... and wide angle view. Endoscopes with working lengths ...
Medicine Products: